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NEMO regulates a cell death switch in TNF signaling
by inhibiting recruitment of RIPK3 to the cell
death-inducing complex II
Alessandra Pescatore1, Elio Esposito1, Peter Draber2, Henning Walczak2 and Matilde Valeria Ursini*,1
Incontinentia Pigmenti (IP) is a rare X-linked disease characterized by early male lethality and multiple abnormalities in
heterozygous females. IP is caused by NF-κB essential modulator (NEMO) mutations. The current mechanistic model suggests
that NEMO functions as a crucial component mediating the recruitment of the IκB-kinase (IKK) complex to tumor necrosis factor
receptor 1 (TNF-R1), thus allowing activation of the pro-survival NF-κB response. However, recent studies have suggested that
gene activation and cell death inhibition are two independent activities of NEMO. Here we describe that cells expressing the IP-
associated NEMO-A323P mutant had completely abrogated TNF-induced NF-κB activation, but retained partial antiapoptotic
activity and exhibited high sensitivity to death by necroptosis. We found that robust caspase activation in NEMO-deficient cells is
concomitant with RIPK3 recruitment to the apoptosis-mediating complex. In contrast, cells expressing the ubiquitin-binding
mutant NEMO-A323P did not recruit RIPK3 to complex II, an event that prevented caspase activation. Hence NEMO, independently
from NF-κB activation, represents per se a key component in the structural and functional dynamics of the different TNF-R1-
induced complexes. Alteration of this process may result in differing cellular outcomes and, consequently, also pathological
effects in IP patients with different NEMO mutations.
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Tumor necrosis factor α (TNF) is a major cytokine promoting
inflammation and innate immune responses. Depending on the
cell type, exposure to TNF can result in either cell survival or
death, reflecting an intricate network of signals that are
triggered by this molecule upon binding to its cognate receptors
of which TNF-receptor 1 (TNF-R1) is the major one.1
Following ligand binding, TNF-R1 undergoes trimerization
and a conformational change that triggers the recruitment of
multiple adaptors, including ubiquitin ligases and kinases,
leading to the formation of the receptor-associated complex I.1
This includes, besides the receptor and the crosslinking
ligand, the adaptor proteins TRADD and TRAF2, the kinase
RIPK1, and the E3 ubiquitin ligases cellular inhibitor of
apoptosis protein (cIAP) 1 and cIAP2. cIAP1/2 mediate the
ubiquitination of several components of the complex I, leading
to recruitment of both the TAK1-TAB1-TAB2 and the linear
ubiquitin chain assembly complex (LUBAC). LUBAC in turn
mediates the formation of linear ubiquitin chains which
enhances recruitment of the IκB-kinase (IKK) complex,
composed of the adaptor protein NEMO (NF-κB essential
modulator) and the kinases IKK1 and IKK2.2 NEMO
specifically binds to non-degradative ubiquitin chains within
the TNF-R1 signaling complex through the cooperation of two
domains: the NEMO ubiquitin-binding domain (NUB, also
called UBAN) and the zinc-finger domain. Together, they
enable efficient recruitment and retention of IKK1/2 and their
activation by the TAK1.3–5 The IKK complex subsequently
activates NF-κB signaling, leading to transcription of pro-
survival genes, such as cIAP1/2, and the cellular FLICE-like
inhibitor protein (cFLIP), an enzyme-inactive homolog of
Caspase-8.6–8
Following internalization of TNF-R1, a cytoplasmic complex
II consisting of RIPK1, FADD (Fas-Associated protein with
Death Domain) and the Caspase-8 is formed.9 Normally,
apoptosis is prevented by dimerization between Caspase-8
and cFLIP. If the cFLIP levels are low, such as in the absence
of NEMO, active dimers of Caspase-8 are formed driving
apoptosis.10 Active Caspase-8 not only initiates the apoptotic
program but also cleaves and inactivates essential necropto-
sis mediators such as RIPK1, RIPK3 and CYLD.11–13
When Caspase-8 activity is compromised, the RIPK1–
RIPK3 oligomerization leads to RIPK3 autoactivation that in
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turn phosphorylates MLKL.14–17 MLKL phosphorylation is the
key event required for its translocation to the membrane where
it triggers plasmamembrane leakage, leading to the execution
of ‘necroptotic’ cell death.18 The interest in necroptosis has
grown substantially as several studies highlighted the impor-
tance of this form of cell death for various physiological and
pathological conditions.19
Incontinentia Pigmenti (IP) (OMIM 308300) is a severe
X-linked dominant neuro-ectodermal disorder, lethal in males,
caused by NEMO mutations. In almost 80% of IP patients, a
common deletion occurs, leading to a truncated and faulty
NEMO protein. Fibroblasts from male fetuses harboring
deleted NEMO show sensitivity to TNF-induced cell death
which is thought to be a consequence of the impaired NF-κB-
mediated induction of antiapoptotic genes.20,21 Several lines
of evidence point towards the possibility that NEMO and
IKK1/IKK2 may also be more directly involved in preventing
TNF-induced cell death in a manner that is NF-κB-
independent.10,22,23 Few NEMO missense mutations have
been reported over the years,24 including A323Pmutation that
was identified in a girl exhibiting the classic IP-skin abnorm-
alities associated with severe neurological defects. This
mutation impairs NF-κB activation, even if it was able to
interact with IKK catalitic subunits 1 and 2. After the discovery
of the NUB domain, it was clearly shown that this mutation
abolished NEMO’s ability to bind to ubiquitin.25–27
Here, we sought to compare the molecular composition of
the TNF-R1-induced signaling complexes and the signaling
outcome triggered by TNF in cells completely devoid of
NEMO, expressing NEMO-WT or the IP-associated NEMO
mutation A323P. We show that NEMO-A323P-expressing
cells are unable to induce NF-κB activation. Despite this, these
cells partially retain the NEMO antiapoptotic function, yet were
markedly sensitized to RIPK3/MLKL-mediated necroptosis.
Thereby, we discover a previously unrecognized transcription-
independent regulatory function of NEMO in TNF signaling,
whose dysregulation contributes to the complexity of diseases
associated with mutations in NEMO.
Results
Cells expressing NEMO-A323P present abnormalities of
cell death induction upon TNF exposure. In addition to
NF-κB activation, TNF is able to induce cell death in a variety
of cell lines. NEMO-deficient cells are unable to activate NF-
κB upon TNF stimulation and succumb to cell death.28 To test
whether expression of NEMO-A323P also has functional
consequences for TNF-induced cytotoxicity, we reconstituted
NEMO-deficient murine embryonic fibroblast (MEF) with
empty vector (herein reported as NEMO-KO), wild-type
NEMO (NEMO-WT) or NEMO harboring the A323P mutation
(NEMO-A323P). Equal expression of NEMO-WT and NEMO-
A323P was assessed by real-time PCR (Supplementary
Figure S1a). NEMO-KO cell were unable to activate NF-κB
upon TNF stimulation and this was rescued by expression of
NEMO-WT, but not by expression of the NEMO-A323P
mutant (Figure 1a). Accordingly, TNF-induced IκB phos-
phorylation and degradation, which occurs in presence of
NEMO-WT, were fully inhibited in NEMO-A323P just like in
NEMO-KO cells (Supplementary Figure S1b). Nevertheless,
all three cell lines were equally able to induce ERK and JNK
phosphorylation upon TNF stimulation, demonstrating that
the lack of TNF-induced NF-κB activation in NEMO-A323P-
expressing cells was not due to unrelated cell-intrinsic
defects (Supplementary Figures S1c).
Remarkably, although both, NEMO-KO and cells expressing
NEMO-A323P, are equally unable to activate NF-κB, their
susceptibility to cell death was significantly different, as NEMO-
KO cells treated with TNF displayed an approximately threefold
increase in the percentage of Annexin-V-stained cells, com-
pared with NEMO-A323P cells that were only marginally
sensitive to TNF-induced apoptotic cell death (Figure 1b).
Interestingly, TNF-induced death ofNEMO-KO cellswas almost
completely prevented by the pan-caspase inhibitor zVAD-fmk
(zVAD), which efficiently blocked TNF-induced Caspase-8
activity in NEMO-KO cells (Figures 1c and d). In contrast, in
NEMO-A323P cells a rapid and exacerbated cell death after
treatment with TNF/zVAD was detected (Figure 1c). This cell
death was blocked by the RIPK1 kinase inhibitor Nec-1
(Figure 1c).29 In line with a protective role of NEMO, NEMO-
KO cells becamemore sensitive to cell death after 24 h of TNF/
zVAD treatment compared with NEMO-WT (Supplementary
Figure S1d). Nevertheless, A323P-NEMO-expressing cells that
were almost completely dead after 6 h of TNF/zVAD treatment,
after 24 h of stimulation became further sensitized to TNF/zVAD
but showed no sensitization to TNF-induced cell death
(Supplementary Figure S1d).
Collectively, these data show that despite the complete
absence of NF-κB activation, cells expressing NEMO-A323P
were not sensitive to TNF-induced apoptosis but they
exhibited a high sensitivity to cell death induced by TNF
and zVAD.
NEMO-A323P interferes with the caspase activation
process. Our data showing that NEMO-KO cells are highly
sensitive to TNF-induced apoptosis are in accord with
previous findings.10 However, the fact that cells expressing
NEMO-A323P were protected from TNF-induced death was
unexpected. Since there seemed to be a decisive difference
in caspase activity between these cells and NEMO-KO cells,
we next investigated whether, and if so how, NEMO-A323P
interferes with the TNF-mediated activation of the proteolytic
cascade conveyed by caspases. As shown in Figure 2a, TNF
treatment induced Caspase-8 cleavage (CC8) in NEMO-KO
cells, yet the Caspase-8 cleavage was drastically reduced in
NEMO-A323P-expressing cells (Figure 2a). Accordingly, we
found that while TNF treatment of NEMO-KO cells resulted in
activation of the Caspase-8 and the executioner Caspases 3
and 7, caspase activation was significantly reduced in
NEMO-A323P-expressing cells (Figures 2b and c).
Although A323P-NEMO is able to bind to the IKK1/2
(Supplementary Figure S2a), the absence of NF-κB activity
is caused by the inability of A323P-NEMO to recognize
ubiquitin.27 Knowing that IKK-kinases prevent RIPK1 kinase-
dependent apoptotic cell death, we next evaluated the effect
of TPCA-1, an IKK inhibitor, on TNF-induced cell death
in NEMO-KO, A323P-NEMO and NEMO-WT cells. As
previously reported,23 pre-treatment with TPCA-1 sensitized
NEMO-WT cells to RIPK1 kinase-dependent apoptosis
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Figure 1 TNF treatment induced different sensitivity to cell death in the NF-κB unresponsive NEMO-KO and NEMO-A323P cells. (a) Nemo(− ) MEF reconstituted with empty
pBabe-puro vector (KO), wild-type NEMO (NEMO) and IP-associated NEMO-A323P mutant (A323P) were treated for 1 h with 10 ng/ml of TNF. Quantitative real-time PCR was
performed in triplicate, and the relative abundance of the indicated transcripts (Icam1 and Nfkbia) was calculated with respect to the expression of Hprt transcript. Error bars
represent S.D. of triplicates experiment. (b) KO, NEMO and A323P expressing MEF cells treated with TNF for 6 h. Apoptosis was measured after double staining with Annexin-V
and PI. Percentage of Annexin-V/PI double-positive cells and Annexin-V positive, PI-negative cells was shown (as indicated). (c) KO, NEMO and A323P cells were pre-incubated
1 h with DMSO, zVAD (20 mM) or zVAD in combination with Nec1 (30 μM), followed by 6 h of TNF (20 ng/ml) stimulation. Identical concentrations of these death-inducing agents
were used in subsequent experiments unless otherwise stated. Relative cell viability was assessed by determining ATP levels with CellTiter-Glo after 6 h of TNF treatment, as a
percentage of untreated cells. Data are presented as mean± S.E.M. (three independent experiments performed), *P-valueo0.01; **P-valueo0.001 (Student’s t-test); NS, not
significant. Cells were observed on a phase-contrast microscope (right panel). Representative images of three independent experiments are presented. (d) KO, NEMO and
NEMO-A323P cells were treated for 2 h with TNF in the presence or absence of zVAD. The luminescence is proportional to Caspase-8 activity, relative light unit (RLU). Error bars
represent S.D. of triplicates of one representative experiment of three
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(Figure 2d and Supplementary Figure S2b). In line with the
absence of IKK-mediated NF-κB activity in both NEMO-KO
and A323P-NEMO expressing cells, we found no additional
effect on cell death and caspase activation after treatment with
TNF in combination with the IKK inhibitor (Figure 2c and
Supplementary Figure S2b).
Thus, the expression of the NEMO-A323Pmutant, although
unable to activate NF-κB, prevents activation of Caspase-8
and, consequently, of downstream caspases upon TNF
stimulation independently of the kinase activities of
IKK1 and 2.
NEMO-A323P inhibits RIPK3 recruitment to the pro-
apoptotic FADD-containing complex. Our results so far
showed that cells expressing NEMO-A323P are protected
from apoptosis, yet surprisingly sensitive to necroptosis in the
presence of zVAD, indicating that NEMO can act as a switch
that determines cell fate during TNF/zVAD stimulation. In
order to understand the mechanism by which this occurs, we
analyzed the composition of the TNF-membrane-bound TNF-
R1 complex I and the cytoplasmic complex II.
The analysis of the TNF-R1 complex I revealed that the IKK
complex was recruited to TNF-R1 complex I only in cells
expressing NEMO-WT but not in NEMO-KO neither in NEMO-
A323P (Figure 3a). In contrast, a stimulus-dependent
recruitment of RIPK1 and SHARPIN into complex I was evident
in all cell types after 5 min of TNF exposure (Figure 3a and
Supplementary Figure S3). Thus, NEMO-A323P is unable to
recruit IKK but does not interfere with recruitment of the
upstream factors RIPK1 and SHARPIN to the receptor,
explaining the block in TNF-mediated NF-κB activation in
these cells.
We next sought to establish whether the presence of
NEMO-A323P affects the composition and functionality of the
complex II formed upon TNF stimulation, promoting caspase
activation. To this aim we immunoprecipitated the complex II
component FADD and observed that 3 h after TNF stimulation,
NEMO-KO cells exhibited substantially enhanced recruitment
of Caspase-8 and RIPK1 to FADD-containing complex as
compared with NEMO-WT (Figure 3b). Strikingly, recruitment
of Caspase-8 and RIPK1 to complex II in NEMO-A323P-
expressing cells was comparable to that observed in cells
expressing NEMO-WT, indicating that NEMO modulates
FADD-containing complex composition and that the A323P
mutant retains this ability. Of note, an increased Caspase-8-
dependent RIPK1 cleavage was revealed in NEMO-KO cells
as compared with NEMO-A323P cells after TNF administra-
tion, further confirming an enhanced Caspase-8 activation in
these cells (Figure 3b). The evidence that NEMO-KO cells are
more prone to form FADD-containing complex upon TNF
Figure 2 The NEMO-A323P interferes with the TNF-induced Caspases activation process in an IKK-independent manner. (a) KO, NEMO and NEMO-A323P cells were
treated with 10 ng/ml TNF for the indicated times (min: minutes). Cells were lysed and subjected to immunoblot analysis for the indicated proteins. One representative of two
independent experiments is shown. (b and c) KO, NEMO and NEMO-A323P cells were treated with TNF for the specified time periods (h: hours) to study the effect of TNF-
induced Caspases activation. Time course of Caspase-8 and Caspase-3/7 proteolytic activity was calculated. In (d), the same cells were treated for 6 h with TNF alone or with
TPCA-1. Caspase-3/7 proteolytic activity was calculated. Data are presented as mean± S.E.M. (three independent experiments performed). *P-valueo0.01 (Student’s t-test)
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stimulation than NEMO-WT and NEMO-A323P cells was
further evidenced by the fact that the recruitment of RIPK3 to
FADD-containing complex after 3 h of stimulation was only
evident in NEMO-KO cells (Figure 3c).
Together, these data show that NEMO, independently from
its ubiquitin-binding domain, prevents recruitment of Caspase-
8 and RIPK3 to the cell death-inducing complex II as revealed
in NEMO-A323P cells.
RIPK3 is able to phosphorylates MLKL outside the FADD-
containing complex. In the absence of caspase activity,
death receptors can still mediate cell death via programmed
Figure 3 The presence of NEMO or NEMO-A323P prevents RIPK3 from integrating FADD-containing complex II. (a) Endogenous complex I pull-down was performed by
Flag-TNF immunoprecipitation in KO, NEMO and A323P-NEMO cells upon different periods of Flag-TNF stimulation (min). Immunoblot analysis for the indicated proteins is
shown. (b and c) KO, NEMO and NEMO-A323P cells were stimulated with TNF (10 ng/ml) for the indicated periods (min). Complex II was isolated by an FADD
immunoprecipitation. Immunoblot analysis was performed to reveal the indicated proteins. Single asterisk indicates modification of RIPK1 when caspases are active and double
asterisks indicate cleaved form of Caspase-8. A representative immunoblot revealing the levels of the indicated proteins is shown. IP, immunoprecipitation; TCL, total cell lysate
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Figure 4 Ser-345 MLKL phopshorylation by RIPK3 is mediated by a RIPK1/RIPK3/MLKL complex. (a) KO, NEMO and NEMO-A323P cells were pre-incubated 1 h with the
indicated compounds followed by TNF stimulation for the indicated time period (hour: h). Immunoblot analysis for the indicated proteins is shown. L.E., long exposure. (b) KO,
NEMO and NEMO-A323P cells were pre-treated 1 h with zVAD followed by a time course (min) with 10 ng/ml TNF. Complex II was isolated by an FADD immunoprecipitation.
Immunoblot analysis was performed to reveal the indicated proteins. (c) siCTR and siRIPK3 Nemo(− ) MEF cells were treated with TNF/zVAD as indicated. The MLKL complex
was isolated by a first immunoprecipitation against MLKL (IP1). The supernatants derived from IP1 were subjected to a second IP against FADD (IP2) to isolate the complex II.
Ifmmunoblot analysis was performed to reveal the indicated proteins
NEMO negatively impacts RIPK3’s apoptotic activity
A Pescatore et al
6
Cell Death and Disease
necrosis.30,31 The fact that NEMO-A323P-expressing cells
did not die after TNF treatment, but were highly sensitive to
necroptotic cell death upon stimulation with TNF in the
presence of zVAD, demonstrated that (i) the residual activity
of Caspase-8 in NEMO-A323P cells was sufficient to prevent
necroptosis following TNF stimulation and (ii) that inhibition of
this residual Caspase-8 activity by zVAD promoted massive
necroptotic cell death. It was previously shown that necro-
some activation requires formation of the RIPK1–RIPK3
heterodimeric amyloid scaffold, leading to activation of RIPK3
which in turn induces necroptosis through MLKL phosphor-
ylation at Ser-345.16,17,32 Consistent with our findings, the
NEMO-A323P cells exhibited significantly enhanced phos-
phorylation of MLKL after 3 h of stimulation with TNF/zVAD
as compared with NEMO-KO cells (Figure 4a). The simulta-
neous inhibition of RIPK1 kinase activity by Nec-1 completely
inhibited MLKL phosphorylation (Figure 4a) and also blocked
cell death (Figure 1c).
The original proposed model of necroptosis induction,
encompasses the stabilization of RIPK1/FADD/Caspase-8,
the subsequent RIPK3 recruitment to the inactive FADD-
containing complex which results in activation of MLKL and
execution of necroptosis.33 Nonetheless, a new scenario
where a RIPK1/RIPK3/MLKL complex is formed in parallel to
the FADD-containing complex has been proposed.16,34 To
gain mechanistic insight on how the phosphorylation of MLKL
occurs, we investigatedwhether RIPK3 is recruited to the FADD
complex in NEMO-A323P cells after TNF/zVAD stimulation.
Upon TNF stimulation, RIPK1 co-immunoprecipitated with
FADD in both NEMO-KO and NEMO-A323P, but not in
NEMO-WT-expressing cells (Figure 4b). Surprisingly, however,
the recruitment of RIPK3 was easily detectable only in NEMO-
KO cells (Figure 4b). In addition, we did not find MLKL in the
FADD-containing complex (Supplementary Figure S4).
The evidence that NEMO-A323P cells were significantly
sensitized to necroptosis but did not show recruitment of
RIPK3 to the FADD-containing complex prompted us to
investigate the possibility that the active necrosome is a
RIPK1/RIPK3/MLKL complex that forms in parallel with but
independently of the FADD-containing complex. To determine
whether the recruitment of RIPK3 to the FADD-containing
complex that we found only in NEMO-KO cells was actively
inducing necroptosis, we assessed the formation of both the
MLKL/RIPK3/RIPK1 necroptosis-inducing signaling complex
and the FADD/Caspase-8 apoptosis inducing complex in
NEMO-KO by performing sequential co-immunoprecipitation
assays. The first MLKL immunoprecipitation showed that the
MLKL/RIPK3 complex was present in resting cells but the
amount of RIPK3 that was associated with MLKL increased
upon necroptosis induction and was also associated with
RIPK1 recruitment. Importantly, these events were linked to
MLKL phosphorylation and were blocked after RIPK3 knock-
down. In contrast, FADD is not recruited to the RIPK3/MLKL
complex (Figure 4c). The second FADD immunoprecipitation
showed that RIPK3 and RIPK1 were associated with FADD-
containing complex but this complex is not the one in which the
phosphorylation of MLKL occurred.
Together with the higher MLKL phosphorylation seen in
NEMO-A323P-expressing cells (Figure 4a), these data show
that RIPK3 and MLKL recruitment to the FADD-containing
complex is not required for RIPK3 activation and induction of
necroptosis but, instead, an independent RIPK1/RIPK3/MLKL
is actively inducing necroptosis.
In the absence of NEMO, RIPK3 promotes apoptosis.
Having demonstrated that RIPK3 recruitment to the FADD-
containing complex only occurred in NEMO-KO cells and that
this event is not necessary for induction of MLKL phosphor-
ylation, we decided to investigate the functional significance
of this event. Sometimes overlooked, RIPK3 was initially
described as a pro-apoptotic molecule as its ectopic
expression in mammalian cells caused apoptosis.35,36
Recently, it was reported that absence of RIPK3 reduced
Caspase-8 activity when cIAP1/2 were inhibited by SMAC
mimetics.37,38 Furthermore, the characterization of RIPK3
inhibitors and of the kinase-inactive RIPK3 mutant (D161N)
revealed a surprising conformational change that promotes a
different form of RHIM-mediated interaction between RIPK1
and RIPK3 leading to FADD/Caspase-8 binding and
apoptosis.39,40 We therefore suspected that RIPK3 recruit-
ment to the FADD complex in NEMO-KO cells might be
responsible for enhanced TNF-induced caspase activation
(Figures 2b and c). Accordingly, the knockdown of Ripk3 by
siRNA resulted in decreased Caspase-3 and -7 activity in
NEMO-deficient MEF cells following TNF stimulation
(Figure 5a), indicating that RIPK3 can promote activation of
apoptosis, independently of its role in promoting necroptosis.
Interestingly, upon TNF stimulation the protein level of
RIPK1 in the absence of NEMO was affected (Figure 5b),
suggesting that NEMO may be involved in the regulation of
RIPK1 stability. This observation is in accordance with
previous work showing that, in the absence of NEMO, RIPK1
is degraded following TNF treatment.4 Despite the fact that
TNF-induced Caspase-8 activation results in RIPK1 cleavage
and its inactivation (Figure 3b), when Caspase-8 was inhibited
by zVAD a dramatic reduction in RIPK1 level in the total
extracts of NEMO-deficient cells (Nemo(− )) was observed
(Figure 5c). Notably, pre-treatment of these cells with either
Nec1, or the proteasome inhibitor MG132, prevented the TNF-
induced decrease in RIPK1 levels in NEMO-deficient cells
(Figures 5c and d). Together, these data indicate that the
absence of NEMO sensitizes to apoptosis in a RIPK3-
dependent manner and causes a partial protection from
necroptosis induced by a complete destabilization of RIPK1
after stimulation with TNF/zVAD.
Discussion
NEMO is the regulatory subunit of the IKK complex, essential
for canonical TNF-dependent NF-κB activation. NEMO-
deficient cells preferentially undergo apoptosis and caspase
inhibition is required to undergo RIPK1 kinase-dependent
programmed necrosis. It was previously proposed that the
activation of NF-κB is a ‘late’ pro-survival checkpoint in the TNF-
R1 pathway and that NEMO also has an ‘early’ pro-survival
function consisting in restraining the death-inducing activity of
RIPK1 upon TNF stimulation, in a ubiquitin-dependent
fashion.10 In the absence of NEMO, RIPK1 engages via
FADD with Caspase-8 leading to apoptosis or slow promot-
ing necroptosis when caspase activity is blocked.10,41
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Nevertheless, a scaffolding role of NEMO in the formation of the
pro-necroptotic TNF-induced complex in MEFs has also been
proposed.22 So far it has been difficult to conciliate the atypical
roles of NEMO in suppressing and activating cell death,
considering its prominent role as a non-catalytic subunit of the
IKK complex, regulating the signal-dependent NF-κB activation
and the IKK-mediating antiapoptotic effects.23
We have examined how the NUB domain mutant, NEMO-
A323P, influences TNF-induced signaling. Although NEMO-
A323P and NEMO-KO cells exhibit a similar defect in NF-κB
activation, as both cell lines are unable to recruit IKK to
complex I of TNF-R1 signaling, we observed a dramatic
difference between cells lacking NEMO or expressing NEMO-
A323P in terms of sensitivity to TNF-induced death. In contrast
to NEMO-KO cells that are prone to TNF-induced apoptosis,
the presence of NEMO-A323P induces: (i) a strong but not
complete protection from TNF-induced apoptosis, indepen-
dent from IKK kinase activity, and (ii) a profound sensitization
to necroptosis when Caspase-8 is inhibited.
Our experiments demonstrate that the composition of the
cytosolic FADD-containing complex in NEMO-KO and NEMO-
A323P cells differs in its ability to promote caspase-dependent
apoptosis. For the first time we have shown that recruitment of
RIPK3 to the FADD-containing complex is detectable only in
the absence of NEMO. We propose that this event enhances
the pro-apoptotic response by bolstering caspase activation.
In contrast, the presence of the NUB mutant NEMO-A323P is
sufficient to inhibit RIPK3 recruitment to the pro-apoptotic
complex, resulting in partial protection from apoptosis follow-
ing TNF treatment. Interestingly, it has recently been reported
that RIPK3, independently from its kinase activity, is able to
contribute to RIPK1-dependent apoptosis induced by treat-
ment with TNF and SMAC mimetics.38
Having demonstrated here that RIPK3 may positively
regulate RIPK1-dependent apoptosis in the absence of
NEMO, it remains to be clarified whether the presence of
NEMO or NEMO-A323P inhibits RIPK3 pro-apoptotic activity
through a direct binding or, indirectly, perhaps via the
interaction of NEMO with RIPK1. Notably, the absence of
NEMO induces a global destabilization of RIPK1 after TNF
treatment. This effect is Caspase-8-independent as it is not
corrected by treatment with zVAD. However, we have found
that the expression of NEMO-A323P prevents RIPK1 degra-
dation. As the RIPK1 scaffolding role and kinase activity are
both important in preventing apoptosis in NEMO-deficient
hepatocytes,42 we speculate that the ubiquitin-binding mutant
Figure 5 RIPK3 has a positive effect on the activation of Caspases in the absence of NEMO. (a) siCTR and siRIPK3 Nemo(− ) MEF cells were treated with TNF (10 ng/ml)
and Caspase-3/7 activation was measured in function of time (h). Error bars represent S.D. of quadruplicates of one representative experiment. Immunoblot analysis was
performed to determine the RIPK3 protein level. (b) MEFs Nemo(− ) or Nemo(+) were stimulated with TNF (10 ng/ml) for 3 h. Immunoblot analysis was performed to determine the
indicated protein levels. (c and d) MEFs Nemo(− ) cells were pre-treated with Nec1 for 1 h and then stimulated with TNF (10 ng/ml) alone or in combination with zVAD, for the
indicated time. Immunoblot analysis was performed to determine the indicated protein levels
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NEMO-A323P is unable to bind to ubiquitinated RIPK1 at
complex I but that it can still interact with RIPK1 via its pseudo-
α-helix.4,25,27 This interaction could in turn enhance the RIPK3
kinase activity and also explain the exacerbated cell death we
observed in NEMO-A323P cells, when an inhibition of
Caspase-8 activity occurs.
The inhibition of Caspase-8 promotes TNF-induced necrop-
tosis by preserving the integrity of RIPK1 and RIPK3.
However, the precise mechanism of RIPK3-mediated phos-
phorylation of MLKL is still unclear.43 Our data reveal that the
phosphorylation of MLKL is barely detectable in NEMO-KO
cells after TNF/zVAD stimulation. We have observed a strong
association between RIPK3 and FADD in NEMO-deficient
cells but we have not detected MLKL in the FADD-containing
complex of NEMO-KO cells, indicating that RIPK3 recruited to
this complex is not associated with MLKL. This has also been
suggested by the fact that RIPK3 recruitment to the FADD-
containing complex also occurs after TNF treatment, a
condition in which RIPK3/MLKL-mediated cell death is
inhibited. Instead, MLKL phosphorylation happens faster
and is strongly amplified in NEMO-A323P cells upon TNF/
zVAD stimulation leading to rapid cell death. In these cells
RIPK3 is not recruited to the FADD-containing complex and
there is no change in the RIPK1 protein level upon stimulation.
Importantly, in the NEMO-KO cells, we have shown that the
RIPK1/RIPK3/MLKL complex forms independently of the
FADD-containing complex and the death signal progresses
after the recruitment of additional molecules of RIPK3 that
ultimately induces MLKL phosphorylation.
Collectively, our results demonstrate that the absence of
NEMO is a condition that is different from the presence of
mutated form of NEMO that is incapable of binding ubiquitin in
terms of sensitivity to different kinds of cell death (Figure 6). In
the presence of NEMO-WT upon TNFor TNF/zVAD treatment,
cell death is inhibited by the consequence of NF-κB activation
and by IKK-mediated inhibition of RIPK1’s kinase activity
(Figure 6, central panel). In the absence of NEMO, TNF
treatment induces assembly of the RIPK1/FADD/Caspase-8
complex that includes RIPK3. Despite the presence of RIPK3,
this complex only induces apoptosis. The presence of NEMO-
A323P prevents RIPK3 recruitment to this RIPK1/FADD/
Caspase-8 complex with the result that its apoptosis-
inducing capacity is limited. This latter condition is similar to
the silencing of RIPK3 by siRNA in NEMO-deficient cells
(Figure 6, left panel). However, in the absence of Caspase-8
activity, the presence of NEMO-A323P promotes RIPK3-
mediated MLKL phosphorylation most probably by preventing
the degradation of RIPK1 (Figure 6, right panel).
Although the role of necroptosis in IP remains unclear, it is
possible that the presence of mutated NEMO inducing amajor
sensitivity to necroptosis triggers some severe aspects of IP,
such as brain atrophy, brain edema and retinal abnormalities.
Furthermore, analyzing to what extent RIP kinases may be
directly involved, and whether necroptosis might contribute to
the pathogenesis of IP, is an intriguing question that deserve to
be addressed in future research.
Materials and Methods
Retroviral transduction of cells. Coding sequence-verified PCR fragments
of NEMO and NEMO-A323P were inserted into the pBABE vector containing the
porumycin resistance as a selectable marker. The pBABE-NEMO vectors and
empty pBABE-puro were used to transfect LinX packaging cells, using a standard
CaPO3 procedure. Conditioned media collected from the transfected LinX cells
after 48 h were filtered through a 0.45-mm pore size syringe filter. This mixture,
supplemented with polybrene (8 mg/ml; Sigma-Aldrich, St. Louis, MO, USA), was
added to recipient cells, NEMO(− ) MEF44 that had been plated at 5 ×105 cells per
100 mm dish the day before infection. Cells were cultured with viral supernatants
for 12 h. After 12 h, the cells were subjected to selection in 2 mg/ml puromycin for
7–14 days. Clones of puromycin-resistant cells were obtained and analyzed for
NEMO expression by real-time and immunoblot assays. Nemo-KO (pBABE-empty),
NEMO-WT and NEMO-A323P reconstituted MEFs were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum, penicillin (50 U/ml), streptomycin (50 mg/ml) and puromycin
(2 mg/ml).
Cell survival and Caspase assay. Cell survival analysis was performed
using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega, Madison, WI,
USA) following the manufacturer's instruction with minor modification.
Caspase-8 or Caspase-3/7 activity was measured using the Caspase-Glo 8 or
Caspase-Glo 3/7 assay kits (Promega) that uses a luminogenic caspase-8 (LETD) or
caspase-3/7 (DEVD) substrate. In both assays, MEF cells were seeded onto 96-well
plates at a density of 8 × 103 cells/well, in triplicates. Twenty-four hours later, cells
were pre-treated with zVAD (20 μM) (Sigma), Necrostatin-1 (30 μM) (Sigma),
TPCA-1 (5 μM) (Tocris, Minneapolis, MN, USA) or DMSO (Sigma) for 1 h and then
stimulated with TNF (20 ng/ml) for period indicated in the figures. Luminescent
reading was carried on the 96-well plate reader (GloMax 96 Microplate Luminometer;
Promega). Apoptotic cells, after TNF tretment, were identified by double staining with
Figure 6 Proposed model of the balance between apoptosis (left panel), survival (central panel) and necroptosis (right panel), in the absence of NEMO, in the presence of
NEMO-WT and of the NEMO-A323P, respectively
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the Annexin V FITC kit, according to the manufacturer’s instructions (Miltenyi Biotec,
Bergisch Gladbach, Germany).
Cell stimulation and immunoprecipitation. For the FADD-containing
complex (FADD-IP), 3 × 106 MEF cells were seeded the day before in a 150 mm
diameter culture dish. Cells were stimulated with recombinant TNF (10 ng/ml) for
the indicated times. Where indicated, before TNF stimulation, cells were pre-treated
with zVAD (Sigma (20 mM)) for 30 min. Cells were lysed in IP-lysis buffer (30 mM
Tris-HCl, pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 10% glycerol, 1% Triton
X-100, EDTA free protease-inhibitor cocktail (Roche, Indianapolis, IN, USA) and 1 ×
phosphatase inhibitor (Sigma)) at 4 °C for 30 min. After incubation on ice and
centrifugation at 20 000 r.c.f. for 10 min, the supernatant was recovered and the
protein concentration determined. Proteins were either directly analyzed, after
electrophoresis, by western blotting or immunoprecipitated. Complex II isolation was
performed by using anti-FADD antibody (Santa Cruz Biotechnologies, Dallas, TX,
USA) coupling to protein G-Agarose beads (Sigma) at 4 °C under rotation. The
following day, the sepharose beads were washed three times with IP-lysis buffer.
After the final wash, proteins were eluted by boiling in reducing sample buffer and
analyzed by western blotting. For the MLKL-IP the anti-MLKL (Abgent, San Diego,
CA, USA) was coupled to protein A-agarose beads. For complex I isolation, cells
stimulation performed with 1 μg/ml Flag-TNF in serum-free medium for the indicated
times. Cells were lysed in IP-lysis buffer (30 mM Tris-HCl, pH 7.4, 120 mM NaCl,
2 mM EDTA, 2 mM KCl, 10% glycerol, 1% Triton X-100 and EDTA free protease-
inhibitor cocktail (Roche)) at 4 °C for 1 h. Flag-TNF (1 μg) was added to the lysates
of non-stimulated control samples. Subsequently, the lysates were centrifuged at
19 000 r.c.f. for 20 min and the TNF-RSC was immunoprecipitated using M2 beads
(Sigma) overnight at 4 °C. The following day, the beads were washed three times
with 1 ml IP-lysis buffer. Proteins were eluted by boiling in reducing sample buffer
and analyzed by immunoblotting. Hek293 NEMO-null cells were transfected as
previously described.26 Membranes were probed with primary antibodies against
following proteins: NEMO (Santa Cruz; sc-8330), IKK-α/β (Santa Cruz; sc-7607),
RIPK1 (BD Biosciences, San Jose, CA, USA; 610459), Caspase-8 (Enzo
LifeSciences), RIPK3 (Enzo LifeSciences), Phospho-JNK (Cell Signaling Technol-
ogy, Denver, MA, USA; 9251), Phospho-ERK (Cell Signaling; 9101), cleaved
Caspase-8 (Cell Signaling; 4927), γ-tubulin (Sigma-Aldrich), phospho-IκBα (Cell
Signaling; 7246), MLKL and Phospho-MLKL(S345) (Abcam, Cambridge, MA, USA;
194699 and 196436), TNF-R1 (Abcam; 19139), (M2) FLAG (Sigma; F3165).
Membranes were then incubated with secondary HRP-coupled antiboidies (Bio-Rad
Laboratories, Hercules, CA, USA).
RNAi-mediated knockdown. MEF cells were seeded at 2 × 105/cells well in
six-well plates. After 6 h of incubation at 37 °C, the cells were transfected with 5 nM
siRNA-targeting RIPK3 or 5 nM non-targeting SiRNA negative control (Silencer
select; Ambion, Life technologies, Carlsbad, CA, USA) by using Lipofectamine
RNAiMAX (Invitrogen), according to the manufacturer’s instructions. After 24 h, the
cells were stimulated with TNF and caspase activity was measured as described
above. Knockdown efficiency was tested by immunoblotting.
Quantitative RT-PCR. MEF cells were left untreated or treated with 10 ng/ml
TNF for the indicated times. Total RNA was extracted from the MEFs using the
RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturer's
instructions with on-column DNase digestion Kit. Total RNA was used to make
cDNA using Superscript III First Strand Synthesis System for RT-PCR (Invitrogen).
Steady-state mRNA abundance was determined by real-time PCR by using Power
SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA, USA) on the
7900HT Fast Real Time PCR System (Applied Biosystems, Foster City, CA, USA),
as described elsewhere,45 using the following primers: Icam1 (5′-TTCACACTG
AATGCCAGCTC-3′; 3′-GTCTGCTGAGACCCCTCTTG-5′); Nfkbia (5′-CTGCAGG
CCACCAACTACAA-3′; 3′-CAGCACCCAAAGTCACCAAGT-5′); Hprt (5′-GGCTTA
CCTCACTGCTTTCC-3′; 5′-CTGGTTCATCATCGCTAATCAC-3′).
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